• Contact Info:
    • RemeGenix, Inc
    4800 Montgomery Lane
    Suite 800
    Bethesda, MD 20814

    Phone: 518-302-1515
    Fax: 301-476-0052

RemeGenix' management team has extensive business and scientific experience. Our executive Team is augmented by Advisory Boards that includes a valuable combination of worldwide leaders in clinical medicine and research. The Scientific team’s research is expanded through collaborations with leading universities and where applicable, contract research organizations with specific expertise required to help us accomplish our milestones.

Andrew Amiel, interim Vice President of Business Development /
  • Strong international investment banking experience across several sectors (Biotech, energy, IT) with an excess of $50M of direct deal flow experience.
  • Co-founder of Lamiel Partners, focused on creating value in biotech through creative financing, deal flow and business development
  • Former Landmark Ventures associate, directly responsible for executing term sheet, partnerships and funding
  • Former Go4Venture Analyst, predominantly focused on fundraising and business plan development
  • Bachelors degree from NYU in Finance and International Business
Advisory Boards (Scientific and Business):
RemeGenix has several individuals serving as advisors to the two co-founders in an unofficial capacity, and is currently in the process of formalizing these relationships and will update the website with their names soon. As the Company grows the members of its advisory board are expected to change over time, as the needs of the Company change.

Reid Adler, J.D. /
  • Reid Adler is the founder of Practical IP Strategy, which advises life science enterprises in strategic planning, IP strategies, and technology transfer.
  • Reid also provides “virtual general counsel” support to technology companies and nonprofits through the Law Office of Reid Adler.
  • Additionally, he is a founder and the CEO of FasterContracts, a new software-as-service business devoted to accelerating and facilitating the negotiation of business agreements.
  • Previously, served in a number of key roles such as:
    • he was the Chief Legal Officer and Executive Vice President of Correlogic Systems, a developer of blood serum-based cancer diagnostic tests,
    • he was the General Counsel and Secretary of the nonprofit genomics research organization, the J. Craig Venter Institute, and
    • he was formerly a partner at Morgan Lewis where he was a co-leader of the law firm’s Life Sciences Practice Group and head of the biotechnology patent practice.
  • Reid also was the founding Director of the NIH Office of Technology Transfer and held that position for five years during the implementation of the Federal Technology Transfer Act.
    • He played a key role in developing model agreements and technology transfer policies for the NIH intramural program, research integrity guidelines for NIH’s extramural grantees, and the Uniform Biological Material Transfer Agreement endorsed by many government labs and academic institutions.
  • He holds a J.D. from The George Washington University Law School and has 30 years of experience in law and business.
  • Reid has testified before Congress on technology transfer policy and has taught courses such as Strategic Planning for the Life Science Enterprise, Technology Transfer and Commercialization, Biotechnology Patent Law and Legal Aspects of Biotechnology at Johns Hopkins, GWU Law School and the FAES Graduate School at NIH.